norco semaglutide – julymd FDA Warns on Certain Forms

this supports the hypothesis that the cardioprotective benefits of GLP-1RA and SGLT2i may be additive

The Big Picture: This milestone opens a new chapter for upstream raw material suppliers and formulation technologists

The lawsuit accuses drug manufacturer Novo Nordisk of failing to warn patients of the possible association between the popular drug and an eye condition called NAION.

Naturally, with all the excitement, were hearing more people ask:Is liposuction still worth it?Or []

I hope my friends in the compounding community call out this type of behavior and if I were one of the manufacturers of current approved GLP-1s (Novo Nordisk, Eli Lilly and Company, etc), I would explore legal action against any company who is blatantly abusing #drugshortage loopholes to engage in manufacturing and not #compounding